David A. Hollander, M.D., M.B.A., is Chief Medical Officer and Senior Vice-President at Ora. David is a board certified ophthalmologist and cornea specialist with expertise in trial design, regulatory strategy, and endpoint selection. In addition to oversight of Ora’s product development programs, David has executive oversight of Ora’s internal R&D group focused on method and model development. Prior to joining Ora, David worked at Allergan for 10 years, serving as VP of Eye Care for Global Medical Affairs and VP and Therapeutic Area Head for Clinical Development and was responsible for global strategy and clinical development programs in anterior segment ophthalmology and consumer eye care.
Dr. Hollander holds an MD from the University of Pennsylvania. He completed a residency in Ophthalmology at the University of California, San Francisco, and a Heed Fellowship in Cornea, External-Ocular Disease, and Refractive Surgery at the Jules Stein Eye Institute, UCLA, where he is an Assistant Clinical Professor of Ophthalmology. He earned his MBA from the Wharton School at the University of Pennsylvania and has a BS in Chemistry from Stanford University.
Dr. Hollander has authored more than 70 papers in peer-reviewed literature and multiple book chapters. He has lectured nationally and internationally on topics ranging from ocular surface disease, genetics, innovative treatments in eye care, and collaborations between academic universities and industry.